This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
AAFP Offers Guidance on FDA Tobacco Regulation
Agency Seeks Public Input on New Authority
By News Staff
The AAFP has weighed in with numerous suggestions to a July request from the FDA for public input on how the agency should implement its newfound authority to regulate tobacco.
The FDA gained the authority to regulate the manufacture, marketing and distribution of tobacco products to protect public health and reduce tobacco use in minors when President Obama signed the Family Smoking Prevention and Tobacco Control Act in June.
In its comments, the AAFP lauded the agency's recent ban on cigarettes with fruit, candy or clove flavoring and suggested the agency go a step further by forcing manufacturers to remove menthol as a flavoring agent.
The Academy also recommended that the FDA
In its comments, the AAFP lauded the agency's recent ban on cigarettes with fruit, candy or clove flavoring and suggested the agency go a step further by forcing manufacturers to remove menthol as a flavoring agent.
The Academy also recommended that the FDA
- ban single sales of little cigars to reduce initiation of smoking among adolescents;
- broaden restrictions on misleading information on cigarette packaging;
- implement pictorial warnings on packaging as a way to broaden communication about the hazards of tobacco use in other countries;
- restrict the use of colors, package design and other attempts to appeal to smokers "through allusions to virility, femininity, glamour," etc.;
- diminish the appeal of tobacco at the point of sale, for example, by requiring that products be sold under the counter; and
- help educate physicians, nurses and other health care providers about tobacco cessation and control.
Academy Ramps Up Stance on Tobacco Cessation, Prevention
The AAFP revised its policy statement on tobacco and smoking and issued a new position paper on tobacco use, prevention and cessation during its annual Congress of Delegates, Oct. 11-14 in Boston.
The revised policy statement calls for a ban on the sale of tobacco products in facilities that provide clinical patient care services, pharmacies and retail outlets with health clinics.
The statement also expanded on the Academy's stance on smoking in movies, calling on the film industry to take the following voluntary steps:
The revised policy statement calls for a ban on the sale of tobacco products in facilities that provide clinical patient care services, pharmacies and retail outlets with health clinics.
The statement also expanded on the Academy's stance on smoking in movies, calling on the film industry to take the following voluntary steps:
- require movies that contain scenes depicting smoking to have an "R" rating unless the presentation of tobacco clearly reflects the dangers and consequences of use or tobacco use is necessary to represent smoking by a historical figure;
- require producers to certify on screen that no one in the production received anything of value in consideration for using tobacco;
- require antismoking ads before all movies that include tobacco use; and
- stop identifying tobacco brands.
The statement also supports the World Health Organization's Framework Convention on Tobacco Control treaty and urges its ratification by the Senate and signature by President Obama.
In its comments, the Academy also expressed hope that FDA officials would find a way to minimize the influence of three nonvoting tobacco industry representatives on its Tobacco Products Scientific Advisory Committee. Those three spots are guaranteed to the industry under the new law, but the Academy cautioned the FDA to limit the role those representatives play.
"Representation by the tobacco industry on National Cancer Institute panels in the past has proven to be detrimental to the work of the agency," the AAFP wrote. "The mission of the FDA and that of the tobacco industry are diametrically opposed, and their presence on the committee will compromise the objectivity of the committee's decisions and tend to create at least an appearance of a conflict of interest."
The Academy also urged the FDA to use caution in setting new standards for tobacco and not allow the industry to make minor, drawn-out changes that accomplish little for public health.
The agency is accepting comments on its new regulatory authority through Dec. 28.
"Representation by the tobacco industry on National Cancer Institute panels in the past has proven to be detrimental to the work of the agency," the AAFP wrote. "The mission of the FDA and that of the tobacco industry are diametrically opposed, and their presence on the committee will compromise the objectivity of the committee's decisions and tend to create at least an appearance of a conflict of interest."
The Academy also urged the FDA to use caution in setting new standards for tobacco and not allow the industry to make minor, drawn-out changes that accomplish little for public health.
The agency is accepting comments on its new regulatory authority through Dec. 28.
Related ANN Coverage
Docs Needed to Spread Tar Wars' Updated Smoke-Free Message
Members Also Can Help by Donating to Program
(9/22/2009)
News Briefs: Government Updates
(6/19/2009)
AAFP Tells Congress: Give FDA Regulatory Authority Over Tobacco
(4/12/2005)
More From AAFP
Tar Wars
Ask and Act Tobacco Cessation Program
Additional Resource
Regulating Tobacco: Q&A with Lawrence Deyton, M.S.P.H., M.D., director of FDA's Center for Tobacco Products
Docs Needed to Spread Tar Wars' Updated Smoke-Free Message
Members Also Can Help by Donating to Program
(9/22/2009)
News Briefs: Government Updates
(6/19/2009)
AAFP Tells Congress: Give FDA Regulatory Authority Over Tobacco
(4/12/2005)
More From AAFP
Tar Wars
Ask and Act Tobacco Cessation Program
Additional Resource
Regulating Tobacco: Q&A with Lawrence Deyton, M.S.P.H., M.D., director of FDA's Center for Tobacco Products
Share this on AAFP Connection
This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Health of the Public
Study: PPI Does Not Routinely Improve Asthma Control
Recalled Oral Contraceptives Pose Pregnancy Risk
CDC to Fund 2D Vaccine Barcoding Pilot
2012 Immunization Schedules Reflect Multiple Changes
Study: Cognitive Decline Detected in Middle-aged Adults
CDC Toolkit Can Help Clinicians Fight Norovirus Infection
Patient-Centered Care Linked to Lower Mortality
Study: Inappropriate Cancer Screenings Continue
Novartis Manufacturing Plant Closes After Drug Mix-ups
FDA Announces Classwide REMS for TIRF Medications
New Infants' Acetaminophen Products Hit Store Shelves
Avoid Environmental Factors Linked to Breast Cancer
Risk for Thrombosis Prompts REMS for Rivaroxaban
Common Drugs Implicated in Most Emergency Hospitalizations
CDC Launches Campaign for Child Medication Safety
HHS Blocks Expanded OTC Access to Plan B
Push Is On to Vaccinate Pregnant, Postpartum Women
FDA Committee Votes to Broaden PCV13 Indication
AAFP Foundation Program Aims to Fight Chronic Disease
NIAAA Alcohol Screening Guide Targets Teens
Walgreens, AAFP Launch Flu Vaccine Pilot in Five States
Helping Patients Quit Smoking Starts With a Question
Trilipix Efficacy in Question, Says FDA
USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening
AAFP Endorses ACP Guideline on ED
ACIP Recommends Expanded HPV, Hepatitis B Vaccination
Bacterial Contamination Spurs Nasal Spray Recall
CDC Renews Call for PCV13 Vaccination
USPSTF Recommends Against PSA Screening
AAFP Supports HHS' Million Hearts Initiative
FDA Phases Out Primatene Mist Inhalers
AHRQ Guides Explain Benefits, Risks of GERD Treatments
Office Champions Project Nets Smoking Cessation Gains
Multiple Lots of Oral Contraceptives Recalled
New Vaccine Review Finds Few Adverse Events
HPV Vaccination Rates Still Lag, Says CDC
Renal Injury Prompts Reclast Label Changes
High-dose Citalopram Linked to Abnormal Heart Rhythms
AHRQ Sleep Apnea Guides Review Diagnosis, Management
Board Chair Spotlights Breadth of Family Medicine Training
USPSTF Softens Stance on Bladder Cancer Screening
HHS Expands Coverage for Women's Preventive Services
Teledermatology Project Aids Underserved Patients